OptimizeRx (NASDAQ:OPRX) Insider Edward Stelmakh Sells 1,388 Shares

OptimizeRx Corp. (NASDAQ:OPRX) insider Edward Stelmakh sold 1,388 shares of OptimizeRx stock in a transaction on Friday, December 19th. The stock was sold at an average price of $13.51, for a total transaction of $18,751.88. Following the completion of the transaction, the insider owned 126,830 shares in the company, valued at approximately $1,713,473.30. The trade was a 1.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

OptimizeRx Trading Up 0.6%

Shares of NASDAQ:OPRX traded up $0.09 on Monday, reaching $13.60. 63,936 shares of the company traded hands, compared to its average volume of 358,041. The stock has a market capitalization of $253.42 million, a P/E ratio of 33.78 and a beta of 1.10. The business’s 50-day simple moving average is $16.56 and its 200 day simple moving average is $15.98. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. OptimizeRx Corp. has a 52 week low of $3.99 and a 52 week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Thursday, November 6th. The company reported $0.20 earnings per share for the quarter, beating the consensus estimate of $0.03 by $0.17. OptimizeRx had a return on equity of 6.37% and a net margin of 0.03%.The company had revenue of $26.07 million during the quarter, compared to analysts’ expectations of $23.83 million. As a group, equities analysts anticipate that OptimizeRx Corp. will post -0.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

OPRX has been the subject of several analyst reports. JMP Securities increased their price target on shares of OptimizeRx from $20.00 to $23.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Citigroup restated an “outperform” rating on shares of OptimizeRx in a report on Friday, October 10th. Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. UBS Group set a $23.00 price objective on OptimizeRx in a research report on Friday, October 10th. Finally, Stephens decreased their target price on OptimizeRx from $20.00 to $17.00 and set an “equal weight” rating for the company in a report on Monday, November 17th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, OptimizeRx presently has a consensus rating of “Moderate Buy” and an average price target of $16.88.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in shares of OptimizeRx by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,059,109 shares of the company’s stock valued at $21,712,000 after purchasing an additional 138,224 shares during the period. Kennedy Capital Management LLC raised its holdings in OptimizeRx by 42.8% in the third quarter. Kennedy Capital Management LLC now owns 674,918 shares of the company’s stock worth $13,836,000 after purchasing an additional 202,446 shares in the last quarter. Parkman Healthcare Partners LLC lifted its position in OptimizeRx by 0.4% during the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after buying an additional 2,188 shares during the period. Manatuck Hill Partners LLC boosted its holdings in shares of OptimizeRx by 3.8% during the 3rd quarter. Manatuck Hill Partners LLC now owns 472,307 shares of the company’s stock valued at $9,682,000 after buying an additional 17,307 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of OptimizeRx by 3.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 397,302 shares of the company’s stock worth $8,145,000 after buying an additional 12,555 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.